Pfizer (NYSE:PFE) Stock Price Up 2.3% - Time to Buy?

Pfizer Inc. (NYSE:PFE - Get Free Report) traded up 2.3% during trading on Tuesday . The stock traded as high as $27.57 and last traded at $27.50. 11,456,110 shares were traded during trading, a decline of 62% from the average session volume of 29,811,535 shares. The stock had previously closed at $26.89.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on PFE shares. Bank of America reiterated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim decreased their target price on shares of Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Cantor Fitzgerald restated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Evercore ISI raised Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. Finally, Citigroup initiated coverage on shares of Pfizer in a research report on Friday, October 25th. They set a "neutral" rating and a $30.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $32.15.

Pfizer Stock Performance

The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business has a fifty day moving average of $26.29 and a 200-day moving average of $28.07. The company has a market cap of $153.69 billion, a PE ratio of 36.65, a P/E/G ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. Pfizer's quarterly revenue was up 31.2% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.34%. Pfizer's payout ratio is currently 232.43%.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the company's stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Swiss National Bank boosted its position in Pfizer by 0.6% during the third quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock worth $486,762,000 after acquiring an additional 100,900 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 11.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock worth $3,766,366,000 after buying an additional 12,864,343 shares during the period. Empowered Funds LLC boosted its stake in shares of Pfizer by 80.9% in the third quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company's stock valued at $14,709,000 after purchasing an additional 227,349 shares during the period. Addison Advisors LLC grew its stake in shares of Pfizer by 394.2% in the third quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company's stock worth $1,512,000 after acquiring an additional 41,668 shares in the last quarter. Finally, KBC Group NV raised its position in Pfizer by 26.0% in the 3rd quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company's stock valued at $89,872,000 after purchasing an additional 639,985 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.